**6. Outlook**

To date, little therapeutic benefit has been gained from this information, since centrally acting sympatho-inhibitory drugs and alpha and beta blockers are used in the treatment of arterial hypertension.

Beta blockers are known to make diabetes worse. On the other hand, quite interestingly, drugs having a central sympatho-inhibitory action, such as clonidine and rilmenidine, are neutral or even slightly beneficial in diabetes and the metabolic syndrome.

Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs) can be extremely effective in regulating the autonomic nervous system and blood pressure. At the same time, some studies indicate that serotonin-norepinephrine reuptake inhibitors (a SNRI) are even more effective.

These data may also lead to the proposal of sympathetically inhibiting drugs of central action in patients with metabolic syndrome in order to reduce the cardiovascular and metabolic consequences and perhaps even better in the unincorporated phases of the MS hoping to reduce the probability of evolution towards the constituted SM.
